Pharmaceutical company Croma Pharma has unveiled the rebranding of its injectable polynucleotide range, PhilArt, to PolyPhil.
The company shares the new name is designed to better reflect the products’ advanced technology and support their expansion into international markets. Croma Pharma’s rebrand aims to strengthen global brand awareness and meet the increasing demand for its polynucleotide treatments, ensuring continued patient satisfaction and clinical outcomes.
Vikki Baker, head of marketing UK&I, said, “With the on-going demand for our polynucleotide portfolio, this name change will better encompass what the product does and will broaden reach in all markets, aiding to global brand awareness. The quality and efficacy of the product remain unchanged and Croma UK will dedicate investment and support for this rebrand.”
